BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 23865835)

  • 21. [Current therapeutic strategies for mantle cell lymphoma].
    Dreyling M; Schnaiter A; Schmidt C; Hoster E
    Internist (Berl); 2016 Mar; 57(3):230-7. PubMed ID: 26886710
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of two doses of intravenous temsirolimus in patients with relapsed/refractory mantle cell lymphoma.
    Jurczak W; Ramanathan S; Giri P; Romano A; Mocikova H; Clancy J; Lechuga M; Casey M; Boni J; Giza A; Hess G
    Leuk Lymphoma; 2018 Mar; 59(3):670-678. PubMed ID: 28768446
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel therapies in mantle cell lymphoma: a pathway to chemotherapy-free strategies.
    Nastoupil LJ; Koff JL; Flowers CR
    Oncology (Williston Park); 2013 Oct; 27 Suppl 2():8-12. PubMed ID: 25374999
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The current therapeutic scenario for relapsed mantle cell lymphoma.
    Ferrero S; Dreyling M
    Curr Opin Oncol; 2013 Sep; 25(5):452-62. PubMed ID: 23872784
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study.
    Lefrère F; Delmer A; Suzan F; Levy V; Belanger C; Djabarri M; Arnulf B; Damaj G; Maillard N; Ribrag V; Janvier M; Sebban C; Casasnovas RO; Bouabdallah R; Dreyfus F; Verkarre V; Delabesse E; Valensi F; McIntyre E; Brousse N; Varet B; Hermine O
    Leukemia; 2002 Apr; 16(4):587-93. PubMed ID: 11960337
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mantle cell lymphoma-management in evolution.
    Rajguru S; Kahl BS
    Chin Clin Oncol; 2015 Mar; 4(1):8. PubMed ID: 25841715
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnosis and treatment of mantle cell lymphoma.
    Hitz F; Bargetzi M; Cogliatti S; Lohri A; Taverna C; Renner C; Mey U
    Swiss Med Wkly; 2013; 143():w13868. PubMed ID: 24226630
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management of relapsed mantle cell lymphoma: still a treatment challenge.
    Ruan J; Coleman M; Leonard JP
    Oncology (Williston Park); 2009 Jul; 23(8):683-90. PubMed ID: 19711582
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mantle Cell Lymphoma: Current and Emerging Treatment Strategies and Unanswered Questions.
    Diamond B; Kumar A
    Hematol Oncol Clin North Am; 2019 Aug; 33(4):613-626. PubMed ID: 31229158
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Emerging agents for the treatment of mantle cell lymphoma.
    Camara-Clayette V; Hermine O; Ribrag V
    Expert Rev Anticancer Ther; 2012 Sep; 12(9):1205-15. PubMed ID: 23098120
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Emerging therapies in mantle cell lymphoma.
    Hanel W; Epperla N
    J Hematol Oncol; 2020 Jun; 13(1):79. PubMed ID: 32552760
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic options for relapsed/refractory mantle cell lymphoma.
    Eyre TA; Cheah CY; Wang ML
    Blood; 2022 Feb; 139(5):666-677. PubMed ID: 34679161
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunotherapy in mantle cell lymphoma: anti-CD20-based therapy and beyond.
    Zhou Y; Zhang L; Romaguera J; Delasalle K; Han X; Du X; Kwak L; Yi Q; Wang M
    Am J Hematol; 2008 Feb; 83(2):144-9. PubMed ID: 17722077
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of hematopoietic stem cell transplantation in patients with relapsed or refractory mantle cell lymphoma.
    Yamasaki S; Chihara D; Kim SW; Izutsu K; Iwato K; Fukuda T; Uchida N; Amano I; Nakazawa H; Kuroda J; Hashimoto H; Ichinohe T; Kanda Y; Atsuta Y; Suzumiya J; Suzuki R
    Ann Hematol; 2018 Aug; 97(8):1445-1452. PubMed ID: 29610968
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic options in mantle cell lymphoma.
    Gill S; Ritchie D
    Leuk Lymphoma; 2008 Mar; 49(3):398-409. PubMed ID: 18297516
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mantle cell lymphoma - Current standards of care and future directions.
    Martin P; Ghione P; Dreyling M
    Cancer Treat Rev; 2017 Jul; 58():51-60. PubMed ID: 28651117
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of targeted treatment in mantle cell lymphoma: is transplant dead or alive?
    Dreyling M; Ferrero S;
    Haematologica; 2016 Feb; 101(2):104-14. PubMed ID: 26830211
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Update on the molecular pathogenesis and clinical treatment of Mantle Cell Lymphoma (MCL): minutes of the 9th European MCL Network conference.
    Dreyling M; Hoster E; Bea S; Hartmann E; Horn H; Hutter G; Salaverria I; Pott C; Trneny M; Le Gouill S; Cortelazzo S; Szymczyk M; Jurczak W; Shpilberg O; Ribrag V; Hermine O;
    Leuk Lymphoma; 2010 Sep; 51(9):1612-22. PubMed ID: 20629519
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current treatment approaches for mantle-cell lymphoma.
    Witzig TE
    J Clin Oncol; 2005 Sep; 23(26):6409-14. PubMed ID: 16155027
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is hematopoietic cell transplantation still a valid option for mantle cell lymphoma in first remission in the chemoimmunotherapy-era?
    Chaudhary L; Kharfan-Dabaja MA; Hari P; Hamadani M
    Bone Marrow Transplant; 2013 Nov; 48(12):1489-96. PubMed ID: 23584438
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.